NCT07114432View on ClinicalTrials.gov

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

August 31, 2028

Conditions
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)
Interventions
DRUG

BCMA/CD19-targeted allogeneic CAR-T

Lymphodepletion chemotherapy followed by allogeneic CAR-T cell (RN1201) infusion

Trial Locations (2)

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Unknown

Tianjin Cancer Hospital Airport Hospital, Tianjin

Sponsors

Collaborators (1)

Allorunning Therapeutics
All Listed Sponsors
collaborator

Allorunning Therapeutics

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER